KYMR vs. ARVN

Last updated Apr 2, 2026

Compare and contrast key facts about Kymera Therapeutics, Inc. (KYMR) and Arvinas, Inc. (ARVN).

Performance

KYMR vs. ARVN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kymera Therapeutics, Inc. (KYMR) and Arvinas, Inc. (ARVN). The values are adjusted to include any dividend payments, if applicable.

KYMR vs. ARVN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
KYMR Kymera Therapeutics, Inc.	9.15%	93.41%	58.01%	2.00%	-60.69%	2.40%	86.41%
ARVN Arvinas, Inc.	-4.47%	-38.13%	-53.43%	20.32%	-58.35%	-3.29%	234.37%

Fundamentals

Market Cap KYMR : $7.17B ARVN : $735.32M
EPS KYMR : -$3.71 ARVN : -$1.15
PS Ratio KYMR : 182.09 ARVN : 3.03
PB Ratio KYMR : 4.54 ARVN : 1.69
Total Revenue (TTM) KYMR : $39.20M ARVN : $262.60M
Gross Profit (TTM) KYMR : $39.20M ARVN : -$398.60M
EBITDA (TTM) KYMR : -$349.40M ARVN : -$84.20M

Returns By Period

In the year-to-date period, KYMR achieves a 9.15% return, which is significantly higher than ARVN's -4.47% return.

KYMR

• 1D: 1.97%
• 1M: -5.74%
• YTD: 9.15%
• 6M: 55.38%
• 1Y: 236.56%
• 3Y*: 42.05%
• 5Y*: 17.18%
• 10Y*: —

ARVN

• 1D: 6.89%
• 1M: -15.38%
• YTD: -4.47%
• 6M: 24.10%
• 1Y: 61.17%
• 3Y*: -25.43%
• 5Y*: -29.66%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

KYMR vs. ARVN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KYMR

KYMR Risk / Return Rank: 96
KYMR Sharpe Ratio Rank: 96
KYMR Sortino Ratio Rank: 97
KYMR Omega Ratio Rank: 95
KYMR Calmar Ratio Rank: 97
KYMR Martin Ratio Rank: 96

ARVN

ARVN Risk / Return Rank: 70
ARVN Sharpe Ratio Rank: 72
ARVN Sortino Ratio Rank: 67
ARVN Omega Ratio Rank: 68
ARVN Calmar Ratio Rank: 72
ARVN Martin Ratio Rank: 70

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KYMR vs. ARVN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and Arvinas, Inc. (ARVN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KYMR	ARVN	Difference
Sharpe ratio Return per unit of total volatility	2.95	0.95	+2.00
Sortino ratio Return per unit of downside risk	4.28	1.51	+2.77
Omega ratio Gain probability vs. loss probability	1.53	1.21	+0.32
Calmar ratio Return relative to maximum drawdown	7.58	1.66	+5.92
Martin ratio Return relative to average drawdown	18.00	3.64	+14.36
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KYMR vs. ARVN - Sharpe Ratio Comparison

The current KYMR Sharpe Ratio is 2.95, which is higher than the ARVN Sharpe Ratio of 0.95. The chart below compares the historical Sharpe Ratios of KYMR and ARVN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	KYMR	ARVN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.95	0.95	+2.00
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.23	-0.43	+0.67
Sharpe Ratio (All Time) Calculated using the full available price history	0.24	-0.06	+0.30

Correlation

The correlation between KYMR and ARVN is 0.48, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

KYMR vs. ARVN - Dividend Comparison

Neither KYMR nor ARVN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

KYMR vs. ARVN - Drawdown Comparison

The maximum KYMR drawdown since its inception was -87.51%, smaller than the maximum ARVN drawdown of -94.37%. Use the drawdown chart below to compare losses from any high point for KYMR and ARVN.

Drawdown Indicators

	KYMR	ARVN	Difference
Max Drawdown Largest peak-to-trough decline	-87.51%	-94.37%	+6.86%
Max Drawdown (1Y) Largest decline over 1 year	-27.74%	-36.90%	+9.16%
Max Drawdown (5Y) Largest decline over 5 years	-83.54%	-94.37%	+10.83%
Current Drawdown Current decline from peak	-10.63%	-89.50%	+78.87%
Average Drawdown Average peak-to-trough decline	-50.63%	-50.42%	-0.21%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.68%	16.86%	-5.18%

Volatility

KYMR vs. ARVN - Volatility Comparison

The current volatility for Kymera Therapeutics, Inc. (KYMR) is 12.83%, while Arvinas, Inc. (ARVN) has a volatility of 19.98%. This indicates that KYMR experiences smaller price fluctuations and is considered to be less risky than ARVN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KYMR	ARVN	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.83%	19.98%	-7.15%
Volatility (6M) Calculated over the trailing 6-month period	46.88%	44.07%	+2.81%
Volatility (1Y) Calculated over the trailing 1-year period	81.27%	64.66%	+16.61%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	74.10%	68.90%	+5.20%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	76.22%	78.34%	-2.12%

Financials